Tumor Necrosis Factor Alpha Inhibition for Inflammatory Bowel Disease after Liver Transplant for Primary Sclerosing Cholangitis
Background. Outcome data regarding the use of tumor necrosis factor alpha inhibitors (anti-TNFα) in patients with inflammatory bowel disease (IBD) after liver transplant (LT) for primary sclerosing cholangitis (PSC) are scant. Methods. We performed a retrospective chart review to investigate outcome...
Saved in:
| Main Authors: | Ravish Parekh, Ahmed Abdulhamid, Sheri Trudeau, Nirmal Kaur |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | Case Reports in Gastrointestinal Medicine |
| Online Access: | http://dx.doi.org/10.1155/2018/1015408 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Clinical association between inflammatory bowel disease and primary sclerosing cholangitis: what changes after colectomy and liver transplantation?
by: Bo Shen, et al.
Published: (2025-08-01) -
The Natural History of Inflammatory Bowel Disease and Primary Sclerosing Cholangitis after Liver Transplantation – a Single-Centre Experience
by: Karli J Moncrief, et al.
Published: (2010-01-01) -
Chromoendoscopy in colorectal surveillance for primary sclerosing cholangitis and inflammatory bowel disease
by: Rodrigo V Motta, et al.
Published: (2025-01-01) -
Characteristics and outcome of primary sclerosing cholangitis associated with inflammatory bowel disease in Asian children
by: Way Seah Lee, et al.
Published: (2019-08-01) -
Primary sclerosing cholangitis–inflammatory bowel disease: Epidemiology, mortality, and impact of diagnostic sequence
by: Kristel K. Leung, et al.
Published: (2025-03-01)